Results 181 to 190 of about 2,195,632 (304)

Sema4A neutralization reduces fibrosis and inflammation in a mouse model of systemic sclerosis and a 3D model of immunity‐driven fibrosis

open access: yesArthritis &Rheumatology, Accepted Article.
Objective We previously showed that Semaphorin4A (Sema4A) is elevated in patients with systemic sclerosis (SSc) and promotes inflammation and fibrosis in vitro. Here, we examined the effect of Sema4A neutralization in vivo and in 3D fibrosis models. Methods Sema4A plasma levels were measured by ELISA in healthy controls (n=31) and patients with SSc (n=
Jaime Marty   +21 more
wiley   +1 more source

Investigating the changes in skin color representation within US medical textbook imagery

open access: yesAnatomical Sciences Education, EarlyView.
Abstract Medical education traditionally relies on textbooks with limited representation of dark skin tones, contributing to “visual racism.” This study sought to answer: “To what extent has skin‐of‐color representation changed in widely used U.S. medical textbooks over twenty years?” Older and newer editions of four widely used medical textbooks were ...
Justin Lyon   +4 more
wiley   +1 more source

Outside‐In Inverted L‐Shaped Capsulotomy in Hip Arthroscopy

open access: yesArthroscopy Techniques, EarlyView.
Abstract Hip arthroscopy has become the mainstream surgical treatment for femoroacetabular impingement syndrome, with approximately 88.75% of patients returning to sports postoperatively. Capsulotomy is a critical step in arthroscopic labral repair; however, various reported techniques possess inherent limitations.
YiSen Feng   +6 more
wiley   +1 more source

Age‐related differences in hydroxychloroquine‐associated adverse events: A pharmacovigilance study based on the FDA Adverse Event Reporting System

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aims This real‐world pharmacovigilance study utilizes FDA Adverse Event Reporting System (FAERS) data (2004–2024) to characterize age‐related disparities in hydroxychloroquine (HCQ)‐associated adverse events (AEs), addressing gaps in age‐stratified risk assessment. Methods Disproportionality analysis (reporting odds ratios, RORs) and parametric Weibull
Guanghan Sun   +4 more
wiley   +1 more source

Efficacy and safety of empagliflozin for treating neutropenia and neutrophil dysfunction in paediatric patients with glycogen storage disease type Ib: A systematic review and meta‐analysis

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aims Glycogen storage disease type Ib (GSD‐Ib) is a rare genetic disorder causing neutropenia and neutrophil dysfunction in children. G‐CSF has been the primary treatment, but emerging data support the potential of empagliflozin, an SGLT2 inhibitor, as a promising investigational option.
Elizabeth Iwasyk   +5 more
wiley   +1 more source

Home - About - Disclaimer - Privacy